How data design shapes confidence in real‑world evidence over time
As precision medicine advances, broad patient populations are increasingly segmented into molecularly defined subgroups based on biomarkers and genomic profiles. While this enables more personalized treatment decisions, it also creates smaller patient cohorts, making real-world evidence generation more difficult. For research teams, that puts cohort definition, comparability and representativeness under growing pressure.
Our new white paper, “Three forces changing how lung cancer evidence is interpreted and applied,” examines how this shift is affecting study design, interpretation and evidence strategy, and how to evaluate whether evidence is likely to hold up outside controlled settings.
In the white paper, you’ll see:
- How incomplete or inconsistent biomarker testing can weaken cohort integrity and study feasibility
- Why shifting sequencing and line-of-therapy patterns can destabilize historical comparators
- Where evidence maturity and population representativeness create risk for interpretation, especially in real-world and HEOR contexts